Articles Referencing ONXX
Wider-than-Expected Loss at ChemoCentryx - Analyst Blog
5/14/2013, 10:55 am from Zacks.com in Investing, Business, Stocks
ChemoCentryx, Inc. ( CCXI ) reported net
loss of 28 cents per share in the first quarter of 2013, wider than
the Zacks Consensus Estimate of a loss of 27 cents but in line with
the year-ago... Read >>
Good News for Cubist Pharmaceuticals - Analyst Blog
5/9/2013, 4:24 pm from Zacks.com in Investing, Business, Stocks
Cubist Pharmaceuticals, Inc. ( CBST ) recently
received encouraging news when the US Food and Drug Administration
(FDA) granted the company's antibiotic candidate
ceftolozane/tazobactam... Read >>
Narrower-than-Expected Loss at ArQule - Analyst Blog
5/9/2013, 1:24 pm from Zacks.com in Investing, Business, Stocks
ArQule, Inc. ( ARQL ) recently
reported a loss of 9 cents per share in the first quarter of 2013,
narrower than the Zacks Consensus Estimate of a loss of 11 cents
per share. The company had... Read >>
Narrower Loss from Onyx, Guidance Maintained - Analyst Blog
5/8/2013, 6:25 pm from Zacks.com in Investing, Business, Stocks
Narrower Loss from Onyx, Guidance
Maintained Onyx Pharmaceuticals Inc. ( ONXX ) reported a loss
of 32 cents per share in the first quarter of 2013, well below the
Zacks Consensus... Read >>
Pharmacyclics Inc. (PCYC): Today's Most Compelling Stock Buy
5/7/2013, 1:53 pm from David Moenning in Investing, Investing Ideas, Stocks, US Markets
SoTM Bull's Eye Report - Today's Most Compelling Buy Tuesday, May 7, 2013 At StateoftheMarkets.com , we strive to "own the best and ignore the... Read >>
Wider-than-Expected Loss at Corcept - Analyst Blog
5/7/2013, 12:25 pm from Zacks.com in Investing, Business, Stocks
Corcept Therapeutics Inc. ( CORT ) posted a loss
per share of 11 cents in the first quarter of 2013, wider than the
Zacks Consensus Estimate of a loss of 10 cents. In the year-ago
quarter,... Read >>
Valeant Misses Earnings and Revenue Estimate in 1Q (Revised) - Analyst Blog
5/7/2013, 9:27 am from Zacks.com in Investing, Business, Earnings, Stocks
Valeant Pharmaceuticals' ( VRX ) first quarter
2013 earnings of $1.27 (excluding special items but including
stock-based compensation expense) were short of the Zacks Consensus
Estimate... Read >>
Positive Opinion on Allergan Candidate - Analyst Blog
5/6/2013, 5:23 pm from Zacks.com in Investing, Business, Stocks
Allergan, Inc. ( AGN ) recently received
encouraging news when the US Food and Drug Administration's (FDA)
General and Plastic Surgery Devices Panel of the Medical Devices
Advisory... Read >>
Perrigo Likely to Report In Line Earnings - Analyst Blog
5/6/2013, 3:23 pm from Zacks.com in Investing, Business, Earnings, Stocks
We expect Perrigo Company ( PRGO ) to report in
line third quarter fiscal 2013 results before the opening bell on
May 7. The company's fiscal year ends on the last Saturday of Jun
every... Read >>
Narrower-than-Expected Loss at Cadence - Analyst Blog
5/6/2013, 1:24 pm from Zacks.com in Investing, Business, Stocks
Cadence Pharmaceuticals, Inc. ( CADX ) posted an
adjusted net loss of 13 cents per share in the first quarter of
2013, narrower than the Zacks Consensus Estimate of a loss of 14
cents. The... Read >>
Questcor Misses on Earnings, Revs - Analyst Blog
5/3/2013, 3:16 pm from Zacks.com in Investing, Business, Earnings, Stocks
Questcor Pharmaceuticals Inc. ( QCOR ) reported first
quarter 2013 adjusted earnings per share of 67 cents, up 15.5% from
the year-ago period. Earnings were, however, well below the... Read >>
Shire Beats Earnings in 1Q - Analyst Blog
5/3/2013, 1:32 pm from Zacks.com in Investing, Business, Earnings, Stocks
Shire's ( SHPG ) first quarter
2013 earnings (excluding special items) of 1.63 as per American
Depositary Share (ADS) beats the Zacks Consensus Estimate of $1.61.
The reported quarter's... Read >>
Valeant Beats Earnings, Misses Revs - Analyst Blog
5/3/2013, 1:31 pm from Zacks.com in Investing, Business, Earnings, Stocks
Valeant Pharmaceuticals' ( VRX ) first quarter
2013 earnings of $1.27 (excluding special items but including
stock-based compensation expense) were short of the Zacks Consensus
Estimate by... Read >>
ViroPharma Reports Loss in 1Q - Analyst Blog
5/2/2013, 1:53 pm from Zacks.com in Investing, Business, Stocks
ViroPharma Inc.'s ( VPHM ) first quarter
2013 adjusted loss (excluding special items but including
stock-based compensation) came in at 7 cents per share compared to
year-ago earnings... Read >>
Allergan Beats on Earnings - Analyst Blog
5/1/2013, 1:03 pm from Zacks.com in Investing, Business, Earnings, Stocks
Allergan, Inc. ( AGN ) reported first
quarter 2013 earnings of 98 cents per share, beating the Zacks
Consensus Estimate of 96 cents per share by 2 cents.
While earnings increased 18.1%... Read >>